We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Daiichi Sankyo Company Ltd (PK) | USOTC:DSNKY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.1672 | -0.61% | 27.2028 | 27.06 | 27.31 | 27.4378 | 27.08 | 27.09 | 195,254 | 21:01:05 |
From Jan 2023 to Jan 2025
By Michael Susin
AstraZeneca said that its drug Enhertu, which it developed in partnership with Daiichi Sankyo, has been approved in the European Union for the treatment of advanced non-small cell lung cancer.
The Anglo-Swedish pharma giant on Monday said that it will receive $75 million from Daiichi as a milestone payment.
AstraZeneca added that the approval comes after positive clinical trial data.
The company added that sales of Enhertu in most of the E.U. territories are recognised by its partner.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
October 23, 2023 02:34 ET (06:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Daiichi Sankyo (PK) Chart |
1 Month Daiichi Sankyo (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
